Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Kazia Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Kazia Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Kazia Therapeutics is high growth as no earnings estimate data is available.
Kazia Therapeutics's revenue is expected to grow by 13.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Kazia Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Kazia Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Kazia Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Kazia Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Kazia Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Kazia Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. James Garner, MA, MBA, MBBS, BSC (Hons), MAICD, has been the Chief Executive Officer, Managing Director and Executive Director of Kazia Therapeutics Limited (formerly Novogen Limited) since February 1, 2016 Dr. Garner serves as Head of the Unit Development Office, AP R&D with Sanofi and is based in Singapore. After qualifying in medicine at Imperial College in London, he spent several years as a practicing clinician in the UK and Australia before joining Bain & Company, a global management consulting company in 2002. He subsequently worked with Biogen and Progen Pharmaceuticals in Australia and with Quintiles, an international clinical research organisation in Singapore. He has broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. He served as Vice President of Medical and Clinical Affairs of Progen Pharmaceuticals Limited from January 29, 2007 to November 2008. Dr. Garner served as Medical Affairs Manager at Biogen Idec for the Asia-Pacific region. At Biogen Idec, he drove the commercial launch of a number of novel biologic therapies in nine Asian countries and also managed regional clinical research and business development activities. Since 2009, he served as Regional Vice President for Takeda Pharmaceutical Company with overall responsibility for all clinical development activities and registration of new chemical entities in the Asian region (excluding Japan), and served as General Manger. Dr. Garner served as a Corporate Strategy Consultant of Bain & Company in Sydney. He began his career practicing medicine at a number of hospitals throughout the United Kingdom and Australia. His previous responsibilities have included leading non-clinical safety and efficacy, phase I-IV clinical trials, product registration, reimbursement, medical marketing and business development. He is a Young Fellow of the Royal Society of Medicine (UK) and a member of the Australian Pharmaceutical Physicians Association. He holds a Bachelor of Sciences (with First Class Honors) from University College, London and a Master of Arts and a Master of Business Administration from the University of Queensland and a Graduate Certificate in Applied Finance and Investment from the Financial Services Institute of Australasia.
James's compensation has been consistent with company performance over the past year.
James's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Kazia Therapeutics management team is about average.
CEO, MD & Executive Director
Director of Finance & Administration
Director of Marketing & Communications
Director of ATM Program
Translational Toxicology Program Director
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Kazia Therapeutics board of directors is less than 3 years, this suggests a new board.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children’s Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children’s Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.